Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen

Journal of Infectious Diseases

Volumn 191, Issue 4, 2005, Pages 596-606

  Matute Bello, Gustavo ^a,c   Liles, W Conrad ^a   Frevert, Charles W ^a   Dhanireddy, Shireesha ^a   Ballman, Kimberly ^a   Wong, Venus ^a   Green, Richard R ^a   Ho, Yeong Song ^b   Witcher, Derrick R ^b   Jakubowski, Joseph A ^b   Martin, Thomas R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY RECEPTOR 3; FAS ANTIGEN; FAS LIGAND; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE MUTATION; LUNG CLEARANCE; LUNG INFECTION; LUNG LAVAGE; MALE; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SPLEEN; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BRONCHOALVEOLAR LAVAGE FLUID; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; LUNG; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOKINES; MUTATION; PHAGOCYTOSIS; PNEUMONIA, PNEUMOCOCCAL; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SPLEEN; STREPTOCOCCUS PNEUMONIAE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13444266337     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427261     Document Type: Article

References (37)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-49.
2. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982; 3:35-56.
3. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000; 21:435-66.
4. Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449-56.
5. Rensing-Ehl A, Hess S, Ziegler-Heitbrock HW, Riethmüller G, Engelmann H. Fas/Apo-1 activates nuclear factor kB and induces interleukin-6 production. J Inflamm 1995; 45:161-74.
6. Takahashi A, Hirata H, Yonehara S, et al. Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8. Oncogene 1997; 14:2741-52.
7. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000; 10:640-8.
8. Park DR, Thomsen AR, Frevert CW, et al. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 2003; 170:6209-16.
9. Matute-Bello G, Liles WC, Steinberg KP, et al. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol 1999; 163:2217-25.
10. Kuwano KN, Hagimoto M, Kawasaki N, et al. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis. Int Arch Allergy Immunol 2000; 122:209-15.
11. Kuwano KM, Kawasaki T, Maeyama N, et al. Soluble form of Fas and Fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 2000; 118:451-8.
12. Matute-Bello G, Winn RK, Jonas M, Chi EY, Martin TR, Liles WC. Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation. Am J Pathol 2001; 158:153-61.
13. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104:13-9.
14. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396:699-703.
15. Connolly K, Cho YH, Duan R, et al. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther 2001; 298:25-33.
16. Wroblewski VJ, Witcher DR, Becker GW, et al. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol 2003; 65:657-67.
17. Wortinger MA, Foley JW, Larocque P, et al. Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology 2003; 110:225-33.
18. Matute-Bello G, Frevert CW, Liles WC, et al. The Fas/FasL system mediates epithelial injury, but not pulmonary host defenses, in response to inhaled bacteria. Infect Immun 2001; 69:5768-76.
19. Grassme H, Kirschnek S, Riethmueller J, et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000; 290:527-30.
20. Markowicz P, Wolff M, Djedaini K, et al. Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome: incidence, prognosis, and risk factors. Am J Respir Crit Care Med 2000; 161:1942-8.
21. Sutherland KR, Steinberg KP, Maunder RJ, Milberg JA, Allen DL, Hudson LD. Pulmonary infection during the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:550-6.
22. Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001; 184:268-77.
23. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
24. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413:732-8.
25. Matute-Bello G, Liles WC, Frevert CW, et al. Recombinant human Fas-ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2001; 281:1328-35.
26. Fine A, Anderson NL, Rothstein TL, Williams MC, Gochuico BR. Fas expression in pulmonary alveolar type II cells. Am J Physiol 1997; 273:L64-71.
27. Hagimoto N, Kuwano K, Miyazaki H, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997; 17:272-8.
28. Hagimoto N, Kuwano K, Kawasaki M, et al. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am J Respir Cell Mol Biol 1999; 21:436-45.
29. Kemp K, Bruunsgaard H, Skinhoj P, Klarlund Pedersen B. Pneumococcal infections in humans are associated with increased apoptosis and trafficking of type 1 cytokine-producing T cells. Infect Immun 2002; 70:5019-25.
30. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukoc Biol 2001; 70:163-70.
31. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
32. Dockrell DH, Lee M, Lynch DH, Read RC. Immune-mediated phagocytosis and killing of Streptococcus pneumoniae are associated with direct and bystander macrophage apoptosis. J Infect Dis 2001; 184:713-22.
33. Hotchkiss RS, Dunne WM, Swanson PE, et al. Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 2001; 294:1783.
34. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-defident mice. Crit Care Med 1997; 25:1298-307.
35. Hotchkiss RS, Chang KC, Grayson MH, et al. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 2003; 100:6724-9.
36. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1:496-501.
37. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999; 96:14541-6.